DrAndrewWeickhardt @WeickhardtOnc

An Australian oncologist with an interest in GU malignancies, phase 1 trials, cycling and having fun with the family Melbourne, Australia Joined May 2012

Tweets

995
Followers

896
Following

334
Likes

900

DrAndrewWeickhardt @WeickhardtOnc

2 months ago

Media hype, bad headlines & euphemisms mask trial truths. @oncology_bg calls for honesty in trials, press, and the clinic. #CommonSenseOncology is needed #ANZUP25 #EndOfLifeCare

0 2 8 684 0

DrAndrewWeickhardt @WeickhardtOnc

2 months ago

BCG + mitomycin C vs BCG similar efficacy, fewer doses—a smart option in BCG shortage era. Combo looks better in patients with CIS and NMIBC. Early biomarker data & AI analysis may personalise NMIBC therapy #ANZUP25 #NMIBC #BladderCancer

0 1 3 190 0

DrAndrewWeickhardt @WeickhardtOnc

2 months ago

MicroRNA-371 is outperforming traditional tumour markers in germ cell tumours. Australian trials like CLIMATE, PRESTIGE will add to data on surveillance & intensification strategies #ANZUP25

0 1 3 178 0

DrAndrewWeickhardt @WeickhardtOnc

2 months ago

New penile cancer models (organoids & PDXs) from fresh tissue now mimic tumor biology & response. A rare cancer, but with big translational potential. A major leap from Mitch Lawrence #ANZUP25 #GUonc #PenileCancer #TranslationalOncology

0 2 5 265 0

DrAndrewWeickhardt @WeickhardtOnc

4 months ago

🧵 Immune resistance in cancer 🛡️ T-cell exclusion? Target macrophages with PI3Kγ inhibitors (e.g. IPI-549) to open the tumor to immune attack. Chronic interferon = double-edged sword. JAK inhibition redirects exhausted T cells back into action. PD-1 + LAG-3 = durable IO ⚡

0 0 1 71 0

DrAndrewWeickhardt @WeickhardtOnc

4 months ago

🚨 IO triplet in RCC hits turbulence Zanzalintinib + nivolumab = 63% ORR, 18.5 mo PFS ?benefit over Cabo/Nivo ?less HFS but similar activity... ➕ Adding relatlimab (triplet) ➡️ lower ORR & PFS 🔁 Rethink LAG3 as target RCC, it's not melanoma 😞 #ASCO25

0 1 3 252 0

DrAndrewWeickhardt @WeickhardtOnc

4 months ago

#SURE2: Sacituzumab + pembro: 44% CR and 71% bladder-intact EFS in MIBC patients refusing cystectomy ✂️ No chemo, no surgery 🔍 Biomarker-driven selection (luminal subtype, TMB) key? Are we ready to skip cystectomy? NMIBC recurrences an issue? urineDNA to confirm CR? #ASCO25

0 1 3 152 0

DrAndrewWeickhardt @WeickhardtOnc

4 months ago

5-yr data from KEYNOTE-564 confirms OS benefit for adjuvant #pembrolizumab in high-risk clear cell #RCC (HR 0.66). DFS & OS gains across subgroups. 🔥 Confirms OS benefit in adjuvant RCC 🧬 But are we overtreating 48% who never recur? #ASCO25 #GUonc #Immunotherapy

0 1 3 199 0

DrAndrewWeickhardt @WeickhardtOnc

4 months ago

🚨 Practice-changing data at #ASCO25 in #CRC 🔹 BREAKWATER: Encorafenib + cetuximab + FOLFOX doubles OS vs SOC (30.3 vs 15.1 mo) in BRAF V600E mCRC. 🔹 CheckMate 8HW: NIVO+IPI shows 54.1 mo PFS in MSI-H mCRC— new IO standard

0 0 1 176 0

DrAndrewWeickhardt @WeickhardtOnc

4 months ago

🚨 KRAS G12C in CRC: Combo strategies evolving fast. 🧪 G12C inhibitors + anti-EGFR (e.g. cetuximab) show synergy (ORR ~46%) 💥 Adding chemo may boost activity—but ⏫ toxicity, dose interruptions 📌 Takeaways: – Drug exposure matters – ctDNA ≠ always concordant #ASCO25

0 0 1 130 0

DrAndrewWeickhardt @WeickhardtOnc

4 months ago

🧬 DYNAMIC-III shows ctDNA-guided chemo escalation in stage III colon cancer did not improve recurrence-free survival vs standard care. But ctDNA clearance post-chemo strongly predicts better outcomes. 40% pts persistent ctDNA despite chemo. Need new options #ASCO25 #CRC

0 1 3 290 0

DrAndrewWeickhardt @WeickhardtOnc

4 months ago

🧬 New hope for GU neuroendocrine carcinomas: DLL3-targeted T-cell engager shows a 40% response rate & ~8mo durability in DLL3-high tumors— outperforming chemo or IO in this poor-prognosis group. Biomarker-driven therapy may be here for small cell GU. #ASCO25 #OncTwitter #GUonc

0 0 3 126 0

DrAndrewWeickhardt @WeickhardtOnc

4 months ago

#ASCO25 Drug development session: Is HER3 the new HER2—or is it too soon? 🧬 HER3-targeting ADCs show promise in NSCLC & SCLC, but biomarker gaps, resistance issues and payload limits remain. “It’s not too early, but it’s not yet.” Lillian Siu

0 0 1 106 0

DrAndrewWeickhardt @WeickhardtOnc

4 months ago

What the #ASCO2025 AI session didn't cover fully (otherwise great talks) 1️⃣ Genomic + multi-omic integration platforms 2️⃣ Health equity & bias audit needs 3️⃣ Clinician AI training urgent 4️⃣ Medico-legal liability frameworks for use 5️⃣ Environmental costs of large models ?🔌☢️

0 0 1 94 0

DrAndrewWeickhardt @WeickhardtOnc

4 months ago

Real-world AI in cancer care: ✅ ↑ in end-of-life discussions via AI nudges ✅ Increase nurse time in care (↓ documentation) ✅ Faster trial screening & protein folding breakthroughs But trust lags behind tech. Transparency, bias control & safety need urgent attention. #AIOnc

0 0 1 45 0

DrAndrewWeickhardt @WeickhardtOnc

4 months ago

🔍 AI in Oncology #ASCO2025 AI isn’t replacing oncologists—it’s augmenting care. Clinical decision support & ambient scribing to trial matching & drug discovery, AI improves efficiency, nudges evidence-based care, and supports overworked teams. Real challenge? Change management.

0 0 2 97 0

DrAndrewWeickhardt @WeickhardtOnc

a year ago

Enthusiastic audience response to #ASCO24 plenary abstracts today. Great that the organisers were able to schedule @TimmyTrumpet @tiesto @Alesso for after party